What is new in the management of rapidly progressive glomerulonephritis?

Clinical Kidney Journal

Volumn 8, Issue 2, 2015, Pages 143-150

  Greenhall, George H B ^a   Salama, Alan D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

AKI; Glomerulonephritis; IgA nephropathy; Systemic lupus erythematosus; Vasculitis

Indexed keywords

BELIMUMAB; BORTEZOMIB; CCX 168; COMPLEMENT COMPONENT C5 INHIBITOR; CYCLOPHOSPHAMIDE; ECULIZUMAB; ERLOTINIB; FOSTAMATINIB; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMATINIB; MYCOPHENOLATE MOFETIL; OCRELIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; ROSCOVITINE; STRESS ACTIVATED PROTEIN KINASE; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DOUBLE FILTRATION PLASMAPHERESIS; DRUG EFFICACY; DRUG TARGETING; EVIDENCE BASED PRACTICE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; IMMUNOADSORPTION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

EID: 84942120931     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv008     Document Type: Article

References (76)

1. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
2. Jones RB, Tervaert JWC, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220
3. Geetha D, Specks U, Stone JH et al. (November 7, 2014) Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol, doi:10.1681/ ASN.2014010046
4. Hu W, Liu C, Xie H et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23: 1307-1312
5. Silva F, Specks U, Kalra S et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement-A prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010; 5: 445-453
6. Han F, Liu G, Zhang X et al. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol 2011; 33: 185-192
7. Jones R, Harper L, Ballarin J et al. A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: 'MYCYC'. On behalf of the European vasculitis study group. Presse Med 2013; 42: 678-679
8. Jayne DRW, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188
9. Walsh M, Casian A, Flossmann O et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84: 397-402
10. Walsh M, Catapano F, Szpirt W et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis. Am J Kidney Dis 2011; 57: 566-574
11. Walsh M, Merkel PA, Peh CA et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): Protocol for a randomized controlled trial. Trials 2013; 14: 73
12. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-721
13. Morgan MD, Drayson MT, Savage COS et al. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 2011; 117: C89-c97
14. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361
15. Laurino S, Chaudhry A, Booth A et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 2010; 25: 3307-3314
16. Schreiber A, Xiao H, Jennette JC et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009; 20: 289-298
17. Xiao H, Dairaghi DJ, Powers JP et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014; 25: 225-231
18. Jayne DR, Bruchfeld A, Schaier M et al. OP0227 oral C5a receptor antagonist CCX168 Phase 2 clinical TRIAL in ANCAassociated renal vasculitis. Ann Rheum Dis 2014; 73: 148
19. Sumida K, Ubara Y, Suwabe T et al. Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibodyassociated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatol 2011; 50: 1928-1930
20. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: Clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18: 1321-1329
21. McIntyre CW, Fluck RJ, Lambie SH. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: An effective treatment. Clin Nephrol 2001; 56: 193-198
22. Lv J, Yang Y, Zhang H et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol 2013; 24: 2118-2125
23. Coppo R, Andrulli S, Amore A et al. Predictors of outcome in Henoch-Schonlein nephritis in children and adults. Am J Kidney Dis 2006; 47: 993-1003
24. Yan L, Junjun Z, Dongwei L et al. Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype. Chin Med J (Engl) 2014; 127: 102-108
25. Ren P, Han F, Chen L et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis. Am J Nephrol 2012; 36: 271-277
26. El-Husseini A, Ahmed A, Sabucedo A et al. Refractory Henoch- Schonlein purpura: Atypical aetiology and management. J Ren Care 2013; 39: 77-81
27. Augusto J-F, Sayegh J, Delapierre L et al. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schönlein purpura in adults: A case series. Am J Kidney Dis 2012; 59: 663-669
28. Pillebout E, Alberti C, Guillevin L et al. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int 2010; 78: 495-502
29. Syeda UA, Singer NG, Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review. Semin Arthritis Rheum 2013; 42: 567-572
30. Shah Y, Mohiuddin A, Sluman C et al. Rituximab in antiglomerular basement membrane disease. QJM 2012; 105: 195-197
31. Bandak G, Jones BA, Li J et al. Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy. Clin Kidney J 2014; 7: 53-56
32. Schless B, Yildirim S, Beha D et al. Rituximab in two cases of Goodpasture's syndrome. NDT Plus 2009; 2: 225-227
33. Mori M, Nwaogwugwu U, Akers GR et al. Anti-glomerular basement membrane disease treated with mycophenolate mofetil, corticosteroids, and plasmapheresis. Clin Nephrol 2013; 80: 67-71
34. Malho A, Santos V, Cabrita A et al. Severe relapsing Goodpasture's disease successfully treated with Mycophenolate Mofetil. Int J Nephrol 2010; doi: 10.4061/2010/383548
35. Kiykim AA, Horoz M, Gok E. Successful treatment of resistant antiglomerular basement membrane antibody positivity with mycophenolic acid. Intern Med 2010; 49: 577-580
36. Lockwood CM, Rees AJ, Pearson TA et al. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976; 1: 711-715
37. Levy J, Turner A. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern 2001; 134: 1033-1042
38. Cui Z, Zhao J, Jia X et al. Anti-glomerular basement membrane disease: Outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine (Baltimore) 2011; 90: 303-311
39. Biesenbach P, Kain R, Derfler K et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption. PLoS ONE 2014; 9: E103568
40. Zhang Y, Tang Z, Chen D et al. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol 2014; 15: 128
41. Farah M, Levin A, Kiaii M et al. Combination hemodialysis and centrifugal therapeutic plasma exchange: 18 years of Canadian experience. Hemodial Int 2013; 17: 256-265
42. Yu F, Tan Y, Liu G et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009; 76: 307-317
43. Chen S, Tang Z, Zhang Y et al. Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol 2014; 38: 445-452
44. Jourde-Chiche N, Daniel L, Chiche L et al. Association between anti-C1q antibodies and glomerular tuft necrosis in lupus nephritis. Clin Nephrol 2012; 77: 211-218
45. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233
46. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-1226
47. Davies RJ, Sangle SR, Jordan NP et al. Rituximab in the treatment of resistant lupus nephritis: Therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22: 574-582
48. Melander C, Sallee M, Trolliet P et al. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4: 579-587
49. Díaz-Lagares C, Croca S, Sangle S et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-364
50. Tang Z, Yang G, Yu C et al. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology (Carlton) 2008; 13: 702-707
51. Mok CC, Ying KY, Yim CW et al. (December 30, 2014) Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann Rheum Dis, doi: 10.1136/annrheumdis-2014- 206456
52. Morimoto S, Watanabe T, Lee S et al. Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus. Mod Rheumatol 2010; 20: 291-294
53. Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritisa randomized trialmultitarget therapy for induction treatment of lupus nephritis. Ann Intern Med 2015; 162: 18-26
54. Mochizuki K, Kayakabe K, Hiromura K et al. Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil. CEN Case Reports 2014; doi: 10.1007/s13730-014-0151-0
55. Mysler EF, Spindler AJ, Guzman R et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum 2013; 65: 2368-2379
56. Navarra SV, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731
57. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930
58. Smith J, McDaid JP, Bhangal G et al. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol 2010; 21: 231-236
59. McAdoo SP, Reynolds J, Bhangal G et al. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. J Am Soc Nephrol 2014; 25: 2291-2302
60. Iyoda M, Shibata T, Kawaguchi M et al. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney Int 2009; 75: 1060-1070
61. Iyoda M, Shibata T, Wada Y et al. Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrol Dial Transplant 2013; 28: 576-584
62. Wallace E, Fogo AB, Schulman G. Imatinib therapy for non-infection- related type II cryoglobulinemia with membranoproliferative glomerulonephritis. Am J Kidney Dis 2012; 59: 122-125
63. Bontscho J, Schreiber A, Manz RA et al. Myeloperoxidasespecific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011; 22: 336-348
64. Henique C, Tharaux P-L. Targeting signaling pathways in glomerular diseases. Curr Opin Nephrol Hypertens 2012; 21: 417-427
65. Flamant M, Bollée G, Hénique C et al. Epidermal growth factor: A new therapeutic target in glomerular disease. Nephrol Dial Transplant 2012; 27: 1297-1304
66. Bollée G, Flamant M, Schordan S et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 2011; 17: 1242-1250
67. Davin J-C. Henoch-Schonlein purpura nephritis: Pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 2011; 6: 679-689
68. Reynolds J, Sando GS, Marsh OB et al. Stimulation of the PD-1/ PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant 2012; 27: 1343-1350
69. Flanc RS, Ma FY, Tesch GH et al. A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int 2007; 72: 698-708
70. Ma FY, Flanc RS, Tesch GH et al. Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab Investig 2009; 89: 470-484
71. Jin M, Xie Y, Li Q et al. Stem cell-based cell therapy for glomerulonephritis. Biomed Res Int 2014; 2014: 124730
72. Huang Z-Y, Hong L-Q, Na N et al. Infusion of mesenchymal stem cells overexpressing GDNF ameliorates renal function in nephrotoxic serum nephritis. Cell Biochem Funct 2012; 30: 139-144
73. Furuhashi K, Tsuboi N, Shimizu A et al. Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages. J Am Soc Nephrol 2013; 24: 587-603
74. Li Y, Yan M, Yang J et al. Glutathione S-transferase Mu 2-transduced mesenchymal stem cells ameliorated anti-glomerular basement membrane antibody-induced glomerulonephritis by inhibiting oxidation and inflammation. Stem Cell Res Ther 2014; 5: 19
75. Gregorini M, Maccario R, Avanzini MA et al. Antineutrophil cytoplasmic antibody-associated renal vasculitis treated with autologous mesenchymal stromal cells: Evaluation of the contribution of immune-mediated mechanisms. Mayo Clin Proc 2013; 88: 1174-1179
76. Sheryanna AM, Smith J, Bhangal G et al. Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis. Nephrology (Carlton) 2011; 16: 410-416